<DOC>
	<DOCNO>NCT01880086</DOCNO>
	<brief_summary>The purpose randomize controlled clinical trial evaluate effect clomiphene citrate compare placebo ( substance without active medication ) men take pain medication ( opioids ) chronic pain condition low blood testosterone level . The condition men low testosterone long-term pain medication ( opioid ) usage call opioid-induced androgen deficiency ( OPIAD ) . Low testosterone cause pain medication effect part brain ( hypothalamic-pituitary axis ) ultimately result decreased testosterone production testis . Typical symptom low testosterone ( hypogonadism ) may include decreased muscle mass , increase fat , osteoporosis , anemia , erectile dysfunction , delay ejaculation . In addition , men low testosterone may experience decreased attention , decrease libido , fatigue , depress mood . Few study look hormonal change cause long-term opioid usage men . Clomiphene citrate , selective estrogen receptor modulator ( SERM ) oral medication inhibits estrogen effect ( feedback ) brain , identify prior study raise testosterone men low testosterone ( due reason chronic pain medication ) . Clomiphene citrate also know lead increase sperm production men low testosterone unlike testosterone topical injection medication . Although clomiphene citrate study hypogonadal men beneficial outcome minimal side effect , group previously study clomiphene citrate treatment patient OPIAD .</brief_summary>
	<brief_title>Clomiphene Citrate Treatment Low Testosterone Associated With Chronic Opioid Pain Medication Administration</brief_title>
	<detailed_description>Chronic nonmalignant pain widespread issue affect 15-30 % population . Many patient chronic pain responsive first-line combination physical modality non-opioid analgesic . Up 20 % patient , however , require opioid therapy adequate pain relief . The use long-acting opioids , include morphine sulfate , oxycodone , fentanyl , methadone , although effective pain control , carry risk addiction , tolerance , systemic side effect include nausea , itching , constipation , hypogonadotropic hypogonadism consequent testosterone depletion ( 86 % patient take chronic pain medication ) lead multiple adverse effect . Opioid-induced androgen deficiency ( OPIAD ) , occurs high frequency persistence , commonly remain undiagnosed pain clinic . Low testosterone may treat use exogenous testosterone ( topical gel ) medication selective estrogen receptor modulators ( i.e . clomiphene citrate ) . While medication type increase serum testosterone level , clomiphene citrate know benefit sperm parameter hypogonadal men exogenous testosterone know inhibit sperm production . Few study examine hormonal change cause long-term opioid usage men , study formally study clomiphene citrate patient population .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Infertility , Male</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male 18 year 65 year Low testosterone define criterion ( serum total testosterone &lt; 350 ng/dl men &lt; 55 year , &lt; 300 ng/dl men 5565 year ) EITHER take opioid pain medication ( see A ) OR plan start new pain medication regimen ( see B ) A ) EITHER continuous opioid treatment chronic nonmalignant pain &gt; =6 month receive one several specify opioid regimen past 1 month ( include &gt; =20 mg/day oral methadone , &gt; =30 mg/day oral sustain release oxycodone , &gt; =30 mg/day oral morphine sulfate , &gt; =6 mg/day oral dilaudid &gt; = 8 mg/day dilaudid ER , &gt; =25 mcg/hr transdermal fentanyl buprenorphine , intrathecal morphine pump ) B ) OR pain management physician plan start pain medication ( opioid nonopioid pain therapy ) receive yet . If case , testosterone check start 1 month pain therapy determine low testosterone qualify begin medication ( clomiphene placebo ) treatment study . BMI ( 2035 kg/m2 ) Presence clear secondary hypogonadism hypogonadal symptom low total testosterone level ( confirmed morning testosterone level &lt; = 350 ng/dL men age &gt; = 55 &lt; = 300ng/dl men age 5565 ) total testosterone &lt; =200 ng/dl ( regardless symptom ) . Additionally LH &lt; 15 mIU ( milliInternational unit ) /mL ( baseline ) . Symptoms hypogonadism include fatigue , decrease energy level/endurance , depress mood , decrease libido , erectile dysfunction . Chronic nonmalignant pain etiology include rheumatoid arthritis , osteoarthritis , spinal stenosis , polymyalgia , complex region pain syndrome I II , neurinoma , phantom limb pain , neuropathic pain origin , scoliosis , neck pain , fail back surgery , chronic pancreatitis . All patient must ability complete study compliance protocol , ability understand provide write informed consent . Chronic pain malignant etiology ( cancerrelated ) Preexisting testosterone deficiency Concomitant use medication could interfere testosterone level include antidepressant medication , spironolactone , cimetidine , clomiphene ( use past 1 year ) , human chorionic gonadotropin ( hCG ) , androgen , estrogen , anabolic steroid , 5alphareductase inhibitor finasteride , dehydroepiandrosterone ( DHEA ) , testosterone therapy ( topical testosterone within 7 day study , injectable testosterone within 6 month study ) , Uncontrolled hypertension Clinically significant abnormal finding screen examination base Investigator 's assessment Known hypersensitivity clomiphene Symptomatic cataract Presence history know hyperprolactinemia without tumor Endstage renal disease Any contraindication testosterone supplementation therapy Absolute contraindication hormone supplementation therapy include active prostate cancer ( suspicion prostate disease unless rule biopsy ) , prostatic specific antigen ( PSA ) &gt; =3.6 , breast cancer , hematocrit &gt; =51 % ( hemoglobin &gt; =17 g/dL ) , uncontrolled congestive heart failure ( CHF ) , myocardial infarction , acute coronary event , unstable angina , coronary revascularization procedure precede 6 month , untreated obstructive sleep apnea , high risk prostate cancer ( ethnicity family history ) , severe low urinary tract symptom ( AUA symptom score &gt; 19 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>Low testosterone</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Opioid analgesic</keyword>
	<keyword>Narcotics</keyword>
	<keyword>Opioid-induced androgen deficiency</keyword>
	<keyword>OPIAD</keyword>
	<keyword>Male infertility</keyword>
	<keyword>Clomiphene citrate</keyword>
	<keyword>Selective Estrogen Receptor Modulators</keyword>
	<keyword>Testosterone replacement therapy</keyword>
</DOC>